Literature DB >> 7634558

Maintaining long-term control of blood pressure: the role of improved compliance.

N Bittar1.   

Abstract

Mild-to-moderate essential hypertension is a major risk factor for stroke and cardiovascular mortality and morbidity. Morbidity can be reduced significantly by lowering high blood pressure, and with the effective antihypertensive drugs now available, it is ever more important to identify and treat the estimated 50 to 60 million hypertensive persons in the United States. Yet a high percentage of persons being treated stop taking their medication and refuse to comply with their therapeutic regimen. Many problems relate to maintaining long-term therapy in the hypertensive population. They include the cost of medication, a lack of written instructions, unclear instructions, noninvolvement of the patient in designing the treatment plan, lack of patient education about the disease, side effects, and inconvenient dosing schedules. Numerous studies have found that compliance increases as drug-dosage frequency decreases, as with the use of once-daily or sustained-release drug preparations. Other contributors to compliance include prescription-refill reminders, appointment reminders, simple written instructions about drug use, and patient education about the need for treatment and the consequences of noncompliance. Many classes of antihypertensive drugs are available, and more are in development. With such an extensive armamentarium available, all patients, regardless of coexisting medical conditions, should be able to be given effective, individualized antihypertensive therapy.

Entities:  

Mesh:

Year:  1995        PMID: 7634558     DOI: 10.1002/clc.4960181504

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  10 in total

Review 1.  Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

Authors:  K A Payne; S Esmonde-White
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 2.  Noncompliance with antihypertensive therapy. Economic consequences.

Authors:  T L Skaer; D A Sclar; L M Robison
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

3.  Compliance and hypertension.

Authors:  F B Garfield; J J Caro
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

4.  Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors.

Authors:  Philip S Wang; Rhonda L Bohn; Eric Knight; Robert J Glynn; Helen Mogun; Jerry Avorn
Journal:  J Gen Intern Med       Date:  2002-07       Impact factor: 5.128

5.  Achieving Adherence After First-Line Antihypertensive Treatment: Should Fixed-Dose Combinations Receive Priority?

Authors:  Kalyani B Sonawane Deshmukh; Jingjing Qian; Kimberly B Garza; Bradley M Wright; Peng Zeng; Cecilia M Ganduglia Cazaban; Richard A Hansen
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-02-24       Impact factor: 3.738

6.  The clinical effects of a new management mode for hypertensive patients: a randomized controlled trial.

Authors:  Yan-Qin Sun; Yong-Ping Jia; Ji-Yuan Lv; Gui-Jin Ma
Journal:  Cardiovasc Diagn Ther       Date:  2020-12

7.  Incremental Blood Pressure-Lowering Effect of Titrating Amlodipine for the Treatment of Hypertension in Patients Including Those Aged ≥55 Years.

Authors:  Barrett W Jeffers; Rahul Bhambri; Jeffery Robbins
Journal:  Am J Ther       Date:  2015 Jul-Aug       Impact factor: 2.688

Review 8.  Identification of validated questionnaires to measure adherence to pharmacological antihypertensive treatments.

Authors:  Beatriz Pérez-Escamilla; Lucía Franco-Trigo; Joanna C Moullin; Fernando Martínez-Martínez; José P García-Corpas
Journal:  Patient Prefer Adherence       Date:  2015-04-13       Impact factor: 2.711

9.  Predictive validity of a medication adherence measure in an outpatient setting.

Authors:  Donald E Morisky; Alfonso Ang; Marie Krousel-Wood; Harry J Ward
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-05       Impact factor: 2.885

10.  Mobile health technology (WeChat) for the hierarchical management of community hypertension: protocol for a cluster randomized controlled trial.

Authors:  Tong Li; Weiwei Ding; Xiaowen Li; Aihua Lin
Journal:  Patient Prefer Adherence       Date:  2019-08-09       Impact factor: 2.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.